This put up was initially revealed on Defender Community
Serena Williams is the most recent public determine to share her expertise utilizing GLP-1 medicines, a category of medication initially designed for diabetes however more and more prescribed for weight reduction.
In an interview with NBC’s At present present, Williams stated she struggled for years to take care of a wholesome weight, significantly after the start of her daughter.
“I simply couldn’t get my weight to the place I wanted to be at a wholesome place and consider me, I don’t take shortcuts. I do every thing however shortcuts,” Williams stated.
Williams revealed she has misplaced 31 kilos since beginning the remedy in 2023. She has additionally partnered with telehealth firm Ro to launch a marketing campaign geared toward lowering stigma surrounding the medicine.
Throughout the US, demand for GLP-1 medicine equivalent to Ozempic, Wegovy and Mounjaro has surged. Nationwide surveys present thousands and thousands of adults have tried the injections for weight reduction, with utilization particularly excessive amongst these dwelling with diabetes, coronary heart illness and different continual circumstances. Black adults are among the many almost definitely to report having used these medicines.
The effectiveness of GLP-1 medicines is broadly reported. Almost two-thirds of customers say the injections helped them shed extra pounds, with present customers extra possible than previous customers to explain the outcomes as “extraordinarily efficient.” Weight reduction usually ranges between 5% and 21% of physique weight, although many sufferers regain weight in the event that they cease therapy. Lengthy-term remedy is usually really useful.
Nonetheless, the associated fee stays a significant barrier. Month-to-month listing costs vary from $936 to $1,349 earlier than insurance coverage, and greater than half of sufferers who’ve used GLP-1s report issue affording them.
Medical doctors usually prescribe the medicine for adults with a physique mass index of 30 or larger, or 27 with weight-related circumstances. Weight problems charges in the US have risen sharply over the previous three a long time, with greater than 42% of adults now affected.
Williams stated her resolution to begin therapy was rooted in her well being struggles. “I had loads of points with my knees, particularly after I had my child. That, fairly frankly, positively had an impact on perhaps some wins that I may have had in my profession,” she stated. “I simply really feel regular once more. It feels actually good.”
Backlash
The tennis star’s followers and followers, nonetheless, don’t appear glad along with her resolution and have been vocal about it on social media.
“Why the f- is there an advert for a GLP-1 with Serena Williams??? A girl with peak bodily health??? This ozempic and weight reduction sh*t is uncontrolled,” stated one X person.
A Rising Market
The marketplace for GLP-1 medicines continues to develop. In 2023, semaglutide-based medicine equivalent to Ozempic and Wegovy generated greater than $21 billion in income for Novo Nordisk, with nearly all of gross sales coming from the US. Eli Lilly’s Mounjaro recorded greater than $5 billion in its first full yr in the marketplace.
Williams stated her purpose now isn’t solely to proceed her well being journey but additionally to assist others really feel empowered to discover the remedies obtainable. By talking out, she joins a rising variety of high-profile figures normalizing conversations round weight, well being and entry to care.
